Small molecules for neurological conditions

Neuropore Therapies is focused on developing innovative therapeutics aimed at halting the progression of neurodegenerative diseases by addressing their underlying causes. The company is advancing several promising drug candidates, including UCB0599, NPT520-34, and NPT1220-478. UCB0599 is currently in Phase 2 clinical trials for early-stage Parkinson's disease. NPT520-34 is an orally bioavailable small molecule that has shown efficacy in reducing neuroinflammation and improving motor function in animal models of Parkinson's disease, ALS, and Alzheimer's disease. NPT1220-478 is a dual antagonist targeting Toll-like receptors 2 and 9, which has demonstrated the ability to reduce inflammation and neurotoxic protein levels in patient-derived neurons, with plans for clinical development anticipated.

In addition to these drug candidates, Neuropore Therapies has developed an integrated autophagy platform that employs high-throughput screening assays to identify novel targets and chemistries for small molecule drug discovery. This platform encompasses various forms of autophagy, including macroautophagy and mitophagy, and is designed to enhance the efficiency of identifying potential therapeutics. The company's research also includes the characterization of small molecules like NPT100-18A, which targets α-synuclein, a protein implicated in Parkinson's disease. This compound has shown beneficial effects in animal models by reducing α-synuclein toxicity, supporting the development of disease-modifying treatments for synucleinopathies.

United States

Neuropore Therapies, Inc. is a San Diego, California based biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics for the treatment Parkinson’s disease and other neurodegenerative disorders. The approaches applied by Neuropore Therapies target the core pathological processes underlying these disorders including the intracellular accumulation of neurotoxic misfolded proteins and neuroinflammation. 

Neuropore Therapies

Company Details